Highlights from AAO 2024
Click Here to Manage Email Alerts
In this episode of Meeting Mic, we bring you pearls and perspectives from the American Academy of Ophthalmology 2024 Meeting with a focus on AMD and retina.
David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration. :28
Douglas Love discusses the company’s phase 3 program in geographic atrophy. 2:37
Pravin U. Dugel, MD, discusses the next steps for the phase 3 SOL-1 and SOL-R studies. 3:54
Jeremiah Brown, MS, MD, presents results from the phase 4 Elevatum trial investigating faricimab for diabetic macular edema. 5:17
Read the full coverage here:
Teleretinal screening for diabetic retinopathy beneficial
Source: Weng CY. The use of teleretinal screening for diabetic retinopathy. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Oral treatment aims to reduce GA progression by slowing vitamin A dimerization
Source: Melamud A. Gildeuretinol in geographic atrophy: Results from SAGA, a 2-year, randomized, double-masked, placebo-controlled Study. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Fas inhibitor shows benefit in some cases of macula-off rhegmatogenous retinal detachment
Source: Borkar DS. Fas inhibition with intravitreal ONL1204 for the treatment of macula-off rhegmatogenous retinal detachment: Results from a phase 2 study. Presented at: American Academy of Ophthalmology meeting; Oct. 18-21, 2024; Chicago.
Collapse
Read more about
Click Here to Manage Email Alerts
